


CellProtect

Nordic Pharmaceuticals AB



Karin Mellström, Ph.D.
CEO

“Developing innovative cell therapies for incurable diseases”

French-Swedish Life Science Day 2017

CellProtect – A Novel NK Cell Therapy

Produced from a Unit of Blood

Cell Therapy

Autologous NK Cells

High Yield & Cytotoxicity

Patented Process & Treatment of Multiple Myeloma

Finalized Ph Ib in MM – no SAE & Signs of Efficacy*

Orphan Drug Designate (EMA – Sep 2017)

Ex Vivo Expanded & Activated

Validated GMP Manufacturing

First Indication Targeted: Multiple Myeloma

First & Only Cell Therapy – Price @ par with Biologics

New Patent Filing Jan 2018

Pivotal Ph II-ready

* Basis for the ODD EMA decision: **“Clinical Data showing complete response”**

Enabling treatment **early** in the disease & in **combination** with other therapies

The Investment Opportunity

Pre-money

SEKm 100/EURm 10

Capital Call Private Placement

SEKm 65/EURm 6.5

Post money shareholding

39%